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Abstract
We have previously developed a diagnostic test for tuberculosis based on detection of my-
cobacterial lipoarabinomannan (LAM) in urine. The method depended on a laborious con-
centration step. We have now developed an easy to perform test based on a magnetic
immunoassay platform, utilizing high avidity monoclonal antibodies for the detection of LAM
in urine. With this method the analytical sensitivity of the assay was increased 50-100-fold
compared to conventional ELISA. In a pilot study of HIV-negative patients with microbiologi-
cally verified TB (n=17) and healthy controls (n=22) the sensitivity of the test was 82% and
the specificity 100%. This is in stark positive contrast to a range of studies using available
commercial tests with polyclonal anti-LAM Abs where the sensitivity of the tests in HIV-
negative TB patients was very low.
Introduction
WHO reports that, if left untreated, each person with active tuberculosis (TB) infects between
10 to 15 new individuals annually. Therefore, effective control of TB requires disruption of
transmission chains, which in turn requires early and accurate detection/diagnosis paired with
appropriate treatment. Despite the enormous global burden of TB, present tests for diagnosis
of active TB have severe limitations, and none are of the most urgently needed point-of-care
(PoC) type [1].
In low income countries the most commonly used diagnostic test still is direct sputum
smear microscopy, a technique that was developed in the 1880s and since then remains largely
unchanged. It only detects about half of pulmonary TB patients and is particularly ineffective
for diagnosis of TB in young children, in patients co-infected with HIV, and in patients with
extra-pulmonary TB. Although it is often described as a simple technology, microscopy re-
quires a high level of training and diligence and is labor intensive.
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Methods that directly/ indirectly measure the presence of tubercle bacilli
A rapid field adapted method that directly or indirectly measures the presence of live tubercle
bacilli in a given host at the sampling time would be the best diagnostic tool for TB control pro-
grams. Basically such a method could aim for detecting either mycobacteria specific antigens
(i.e. immunologically active components of Mtb) in the infected host (urine, blood, sputum,
cerebrospinal fluid or homogenates from biopsies) or nucleic acids, or possibly Mtb specific an-
tibodies. There have been many attempts to use determination of specific antibody titers (dif-
ferent ELISA, EIA formats) to diagnose TB both in man and animals. So far none of these
methods have proven specific or sensitive enough to be of any diagnostic value. In fact, WHO
has formally rejected the use of such current tests for humans [2].
Detection of mycobacterial antigens in urine as a diagnostic test has several potential advan-
tages compared with all currently used diagnostics. Urine samples are simple to collect, process
and store. Urine is a particularly attractive specimen in young children, who are unable to
produce sputum.
The major Mtb surface antigen is lipoarabinomannan (LAM), which is the major glycolipid
surface component of the Mtb cell wall and may account for up to 15% of the total bacterial
weight. LAM consists of a mannan polysaccharide backbone with branched oligoarabinosyl
containing saccharide side chains; the former is covalently linked to a phosphatidyl inositol
lipid moiety [3–5]. During TB disease LAM in a soluble form is released both from metaboli-
cally active and degrading bacterial cells [6,7]. Hence, we assumed that in active TB disease
LAM occurs in serum and subsequently may be cleared through the kidneys and occur in urine
in an antigenically intact form. Furthermore, as LAM is a carbohydrate antigen, and thus in-
herently heat-stable, LAMmay be detectable by sensitive immunological techniques, even after
heat treatment of urine samples. At least in theory, the amount of LAM in the urine should
reflect the bacterial load, metabolic activity and/or rate of degradation of the bacteria, and
hence permit a semi-quantitative assessment of the infectious status and response to anti-
bacillary treatment.
In 2001 we reported that LAM was indeed excreted in urine from mice experimentally inoc-
ulated with Mtb [8] and in patients with active TB [8] using: i) an antigen capture ELISA, and
ii) a dipstick test utilizing polyclonal antibodies raised against LAM. In the antigen capture
ELISA the original urine samples were boiled, desalted and concentrated 50-fold.
Subsequently field studies in Ethopia [9,10] showed that by using the antigen capture
ELISA and applying the laborious concentration of urine, proof of concept was established and
showed a relatively high specificity (83%) and a sensitivity of 66%, indicating that a more sensi-
tive assay using a less complicated concentration technique should work as a PoC test.
Based on these early data, a urine LAM ELISA test was produced by Chemogen Inc. (Port-
land, ME, USA) and a commercial version of this test was marketed as the Clearview TB ELISA
[(Alere Inc. (formerly Inverness Medical Innovations Inc.), Waltham, MA, USA]). Unfortu-
nately this test has certain deficiencies, since polyclonal rabbit antibodies (Abs) of low avidity
and specificity were used [11]. The Clearview LAM test has generated a series of clinical stud-
ies, and a systematic review and meta-analysis regarding the use of the test was published in
2011 [12]. Thus in seven studies, assessing test accuracy in microbiologically confirmed cases
only, estimates of sensitivity ranged from 13% to 93% and specificity from 87% to 99%. When
results were stratified by HIV status in five studies, mean sensitivity in HIV-negative patients
was 14% (range 7–24%) and in HIV-positive patients 51% (32–69%). The sensitivity of the test
was 3–53% higher in HIV-positive than HIV-negative subgroups and was highest with ad-
vanced immunosuppression [12]. This review concluded that the Clearview ELISA test had
several characteristics that made it attractive for diagnosing active TB, but that it had
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suboptimal sensitivity for routine clinical use (11). The Clearview as well as a strip test
(Alere Determine TB LAM Ag test) are however sold for TB diagnosis in HIV patients with
advanced immunosuppression.
It seems clear that this type of test has good potential for PoC of TB, but that an increase in
sensitivity is needed, as well as further development to make it reproducible and feasible for
large-scale production, providing speed, ease-of-use, low cost and robustness.
To reduce the time required for target detection, a minimal amount of sample manipulation
is essential. The sensitivity of the detection method has to be high enough to reduce/eliminate
the need for target amplification and complicated enrichment steps.
To this end we produced monoclonal Abs (mAbs) directed against LAM [13], using in-
house produced immunogens. This work resulted in a large series of mAbs of extremely high
avidity and affinity. Clones were transferred to Genovac (now Aldevron Freiburg, http://www.
aldevron.com/antibody/overview/) for large scale preparation of mAbs, and ELISA technology
was transferred to Future Diagnostics (http://www.future-diagnostics.nl) to set up production of
a standard antigen capture ELISA test based on these high avidity mAbs. This LAM ELISA test
was evaluated by FIND in several test sites in Africa but sensitivity still proved to be inadequate
for routine diagnosis (unpublished data). However, our anti-LAMmAbs were used in the devel-
opment of a single-molecule sensitive fluorescence-linked immunosorbent assay as an analytical
platform for the detection of LAM. This format proved to be about 3 orders of magnitude more
sensitive than the comparable standard ELISA assays [14]. Samples containing as little as 600
LAMmolecules per μl produced a distinct signal. This methodology, although it requires rela-
tively sophisticated and expensive equipment, served as an additional proof of principle that the
sensitivity of our diagnostic approach could be increased by making use of this anti-LAMmAb.
Based on our concept of detection ofMtb specific antigens in body fluids we have developed
simple amplification methods in order to detect LAM in samples from both smear-positive
and smear-negative TB patients. We describe a magnetic immunoassay platform, utilizing
magnetic nanoparticles (MNP) in order to concentrate the antigen. With this method we have
increased the analytical sensitivity of the assay 50-100-fold compared to conventional ELISA.
Materials and Methods
Ethics statement
The Regional Ethical Review Board at Karolinska Institutet in Stockholm approved of the
study. Patients were included after giving their verbal and written informed consent when the
nature and possible consequences of the study had been fully explained. Laboratory samples
were coded and analysed in a blinded fashion.
Material and Reagents
Magnetic nanoparticles (MNP) were purchased from Chemicell GmbH/Germany.
mAbs CSU-35 and CSU40 (directed at LAM) produced under the NIH, TBVTRM Contract
with Colorado State University (CSU) were used as reference mAbs.
Preparation of anti-LAMmAbs
Cell wall preparations from Mtb H37Rv were isolated and LAM was purified [15], and anti-
LAMmAbs were produced as previously described [13]. The isotypes of the mAbs were identi-
fied by ELISA, using alkaline phosphatase-conjugated goat antimouse IgG subclass specific
antibodies (Sigma Chemical Co, USA) and LAM as coating antigen. The mAbs of IgG1 sub-
class with highest affinity were chosen for further studies.
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Assessments of the titre and avidity of the anti- LAMmAbs
1. ELISA. The relative titres of the mAbs were determined by ELISA. Wells of polystyrene
microplates (Maxisorb, Nunc, Denmark) were coated with 100 μl of purified LAM (10 μg/ml)
in 0.05 M carbonate buffer, pH 9.6, at room temperature overnight. The plates were washed
three times with rinsing buffer (PBS containing 0.05% Tween), and then blocked with 0.5% ca-
sein for 1 h at 37°C. After washing, 100 μl of serial dilutions of each mAb were added to the
wells and incubated for 1 h at 37°C. After washing with rinsing buffer, 100 μl of alkaline phos-
phatase-conjugated goat antimouse IgG (Sigma Chemical Co., diluted 1/2000 in PBS) was
added to each well and the plates were incubated for a further 1 h at 37°C. After subsequent
washings, the plates were developed at room temperature using p-nitrophenyl phosphate
(Sigma Chemical Co.) as substrate and the colour reaction was measured by increase in absor-
bance at 405 nm using an ELISA reader (Dynatech, MR 5000).
2. Surface Plasmon Resonance (SPR). The interaction between mAbs and LAM was ana-
lyzed using surface plasmon resonance (SPR) (Biacore 2000; Biacore, GE Healthcare, Uppsala,
Sweden) in order to identify the mAbs displaying the highest avidity.
Six mg of LAM was delipidated by alkaline treatment with 0.1 M NaOH for 1 h at 80°C. The
pH of the suspension was adjusted to 6.0 with 1 M HCl and the lipid precipitate was removed
by centrifugation. The delipidated LAM (dLAM) was then treated with 0.05 M periodate for 15
min at 4°C in the dark with stirring. After stopping the reaction with 100 μl of ethylene glycol
the activated AM purified on a PD-10 column equilibrated with 0.1 M sodium bicarbonate
buffer at pH 8.3.
After testing various linkers for immobilization of the activated AM to the gold surface,
cystamine activation of the gold surface was chosen, introducing a 2- carbon atom long spacer
arm, leaving free amino groups available for covalent conjugation to the activated AM.
The sensor chips were coated with different concentration of activated AM ranging from
0.1–0.5 mg AM on carbohydrate basis. After incubation over night at ambient temperature in
the presence of 20 mg/ml sodium borohydride the chips were rinsed twice with PBS and the re-
maining sites on the chips were blocked with 5 mMmercapto ethanol for 20 min. The chips
were then washed gently with PBS and air-dried for 2 h at room temperature. The chips were
then blocked with 0.5% casein at room temperature for 1 h. After rinsing 100 μl of biotinylated
anti-LAM antibody, 2ug/ml was added onto the surface of each chip. After 1 h incubation the
chips were rinsed with PBS-Tween buffer. Next, the chips were incubated with 100 μl of
avidin-HRP at 1:5000 dilution. After 1 h incubation the chips were rinsed gently with washing
buffer and 100 μl of TMB substrate was loaded on the surface of the chip followed by 15 min
incubation. The blue solution developed on the chip surface was then transferred into the wells
of a microtitre plate and the reaction stopped with 50 μl of 16% sulphuric acid. The absorbance
was recorded with an ELISA reader at 450 nm.
Avidity assessment of mAbs was performed using BIAcore 3000 at 30°C in PBS at 20 μl/min
flow rate, and a total injection of 20 μl. For regeneration of the sensor chips different buffers
were examined: glycine-HCl buffer at pH 1.5, 2.0, 2.5 and 3, and 3 M guanidine hydrochloride
and 100 mM sodium hydroxide. The best condition for regeneration was 100 mMNaOH,
which was then always used.
Synthesis of gold (Au) coated MNP particles and Au MNP—mAb
conjugate for the Uri-TB-direct test
MNP particles (1013) were resuspended in 5 ml toluene and the solution was heated to 85°C.
HAuCl4 3H2O (0.05 g) and oleylamine (1.25 ml) in toluene (5 ml) were injected to the
mixture while maintaining the temperature at 85°C for 1 h. The solution was cooled to RT to
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produce a dark purple solution. The particles (0.1 g) were dissolved in 20 ml phenyl ether and
then mixed with 2 ml oleic acid (6 mM) and 2 ml oleylamine (4 mM) under N2 with vigorous
stirring. 1,2-Hexadecanediol (2.85 g) was added to the solution and heated to 120°C under re-
flux for 2 h, then cooled to RT. The Fe3O4-Au NPs were precipitated in ethanol (approx 15 ml)
and separated by either centrifugation or by a permanent magnet. The pellets were washed
twice with ethanol and re-dispersed in 3–5 ml water. Tri-sodium citrate (0.04 g) was added and
the pH of the resulting solution adjusted to 6.5. The solution was sonicated for 15 min in ultra-
sonic bath and the particles were collected by magnet or centrifugation and re-dispersed in
water and sonicated again for another 15 min.
UV/visible spectra were obtained using a Molecular Devices Spectromax 384 spectrometer.
TEM images were obtained using an FEI Tecnai G2 120 kV TEM operated at 100 kV and visu-
alized using analySIS software. MAbs were immobilized to the surface of the gold coated parti-
cles by an in house method (US Patent 6165468).
Uri-TB-direct assay
The Au-MNP mAb particles were used in an assay to detect LAM in urine by detecting anti-
body-Mtb complex signals. Five ml urine samples were boiled for 15 min and after chilling
they were placed in 10 ml tubes and 10 μl of the MNP-AB-Conjugate was added to each urine
sample. The tubes were incubated for 15 min and then placed in a magnet-stand for 3 min. The
supernatant was then removed and the particles were washed with 4 ml of PBS/Tween solution.
This procedure was repeated once. Then 500 μl of a biotin-labelled mAb solution was added to
each tube, vortexed briefly and incubated for 10 min. After washing, a Streptavidin-HRP Con-
jugate (500 μl) was added to each sample and incubated for another 10 mi. After washing
200 μl of SURE Blue TMB reagent was added per sample tube and incubated for 5 min in the
dark. 100 μl of the coloured supernatant was placed in a well of a 96-well plate; 50μl of Stop Re-
agent was added and absorbance was read at 450 nm.
Urine samples from patients and controls
At the TB clinic, Karolinska University Hospital, Stockholm, urine samples were collected
from 17 HIV-negative adult patients (age 22–63 years) with culture and/or PCR confirmed TB
(9 with pulmonary TB, and 8 with extrapulmonary TB). From each patient one random urine
sample was collected in a 50 cc polypropylene tubes before onset of TB treatment. Samples
from 22 adult TB naïve healthy individuals (age 28–60 years) were collected from hospital staff
at South Hospital, Stockholm, All samples were immediately frozen at—20°C, and tested with-
in one month.
Results
Binding capacity of mAbs
SPR analysis revealed two mAbs out of 22 (mAb 25 and 170) with the highest avidity kD value of
3.9 x 10-8 and 8.0 x 10-7 respectively. These two mAbs also showed the best binding capacity to
the LAM antigen (Fig 1). The ELISA titration curve of the same two mAbs when compared to the
reference anti-LAMmAbs CSU-35 and CSU40 showed 3 logs higher binding capacity (Fig 2).
Analytical sensitivity for detection of LAM by ELISA using mAbs
Using the high avidity mAbs 25 and 170 and urine spiked with LAM at increasing concentra-
tions the detection limit was estimated at 1 ng/ml in ELISA (Table 1).
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Analytical sensitivity of the Uri-TB-direct test format
By utilising the Au-MNP, with MAb25 as capture and MAb170 as developer mAb, the detec-
tion limit was increased 50 fold compared to the ELISA (Table 1), reaching a detection limit of
0.05 ng/ml when using a volume of 5 ml of urine. The starting amount of processed urine had
an important effect on the detection limit of the Uri-TB-direct assay (Table 2). Thus the detec-
tion limit was 10 times higher when 0.5 ml urine was used as starting material, compared to
when 5 ml urine was used.
LAM detection by Uri-TB-direct in TB patients and controls
By reading the absorbance at 450 nm a cut-off value for the sensitivity and specificity was set at
an optical density (OD) of 0.35. Among urine samples from 22 healthy individuals analysed all
were negative (mean OD was 0,17; range 0.12–0.30) (Table 3). Of the 17 urine samples from
HIV-negative patients with culture confirmed TB 14 (82%) generated a positive result (mean
OD was 0,49; range 0,21–1,36) (Table 4). Two of the 17 patients were sputum smear microsco-
py positive by concentration, and both these were LAM positive.
Discussion
We have developed a new format of a LAM detection test, using mAbs with extremely high
avidity, and increased the signal by using new nanotechnology techniques. The format of the
Uri-TB-direct platform makes the test easy to perform. It includes a few pipetting and washing
Fig 1. Kinetics of mAb binding to immobilized LAM at various mAb concentrations using Biacore.
doi:10.1371/journal.pone.0123457.g001
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steps. A technician can handle 24–48 samples in about 2 h. In this study an ELISA reader was
used in order to do a quantitative measurement of the LAM concentration, however, for field
purposes, the ELISA reader can be replaced by either: 1) a battery operated portable ELISA
reader (cost about 500 USD), or ii) by reading the colour change by the naked eye. In that case,
no electricity is needed.
Table 1. Detection of LAM by ordinary ELISA and the Uri-TB-direct test at various concentrations of
LAM (ng/ml).
LAM-spiked urine ng/ml ELISA Uri-TB-direct
10 2.78* > 5.0
5 2.07 > 5.0
2.5 1.01 > 5.0
1 0.51 4.41
0.5 0.36 3.47
0.25 0.32 2.34
0.1 0.33 1.44
0.05 0.36 0.79
0 0 0.38
Results in optical density (OD) by the two different methods. The detection limit for the ELISA is 1 ng
LAM/ml and for the Uri-TB-direct assay  0.05 ng LAM/ml.
* OD at absorbance 450 nm
doi:10.1371/journal.pone.0123457.t001
Fig 2. ELISA titration curve of inhouse Anti-LAMmAbs 25 and 170 compared to the reference anti-
LAMmAbs CSU-35 and CSU-40.
doi:10.1371/journal.pone.0123457.g002
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The amount of excreted LAM has been reported to vary between 1 ng/ml (i.e. the detection
limit of the tests used) and several hundred ng/ml [16–18], depending on the clinical manifes-
tations. Quantitative LAM detection results increase with bacterial burden [19]. Thus, smear
positive patients have been shown to be more often positive in LAM ELISA than smear nega-
tive patients [17,20,21], and a positive correlation between bacterial density in sputum and
urine concentration of LAM has been demonstrated [17]. The sensitivity of urine LAM testing
increases with progressive HIV immune suppression (as reflected by falling CD4 cell counts),
Table 2. Effect of urine volume on detection limit of the Uri-TB-direct assay.
LAM ng/ml 0.5 ml 2 ml 5 ml
10 > 5 * > 5 > 5
5 1.4 > 5 > 5
1 0.34 2.2 4.4
0.5 0.13 0.96 4.1
0.25 0.13 0.44 1.96
0.12 0.13 0.17 1.1
0 0.13 0.18 0.22
* OD at absorbance 450 nm
doi:10.1371/journal.pone.0123457.t002
Table 3. Detection of LAM by the Uri-TB-direct test in urine of healthy controls.
Individual Uri-TB-direct (OD)
1 0,16
2 0,19
3 0,2
4 0,14
5 0,2
6 0,15
7 0,18
8 0,3
9 0,18
10 0,16
11 0,18
12 0,15
13 0,12
14 0,2
15 0,2
16 0,15
17 0,14
18 0,14
19 0,16
20 0,13
21 0,21
22 0,19
Mean OD 0,17
Results in optical density (OD) at absorbance 450 n.
doi:10.1371/journal.pone.0123457.t003
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probably correlating with an increased total mycobacterial burden [18], and the concentration
of LAM in urine is associated with poor prognosis in patients with HIV-associated TB [22].
Since the LAM concentration in urine of non-HIV co-infected TB patients is extremely low,
in many cases in the range of picogram per ml, the “ordinary” LAM test (ELISA or strip test),
which detects LAM in the range of nanogram per ml, is not sensitive enough for diagnosis in
unselected TB suspects. In this study we demonstrate how one may achieve a 50-100-fold in-
crease in urinary LAM detection using our Uri-TB-direct assay compared to previous methods.
In our previous reports using a sandwich ELISA with polyclonal antibodies, the detection
limit of LAM in spiked samples was 1 ng/ml [8]. By using a laborious concentration step the
analytical sensitivity of the test was increased to 20 pg/ml of urine [8,10]. In those studies the
samples were boiled and then centrifuged after which the supernatant was further purified
through column chromatography and the eluent was concentrated 50-fold by a rotavapor.
With this concentration procedure the sensitivity of the test was estimated to be 81% in sputum
smear positive Ethiopian TB patients [10]. However, this laborious method is not suited for the
development of an easy to use POC test. The detection limit of our earlier sandwich ELISA
using polyclonal Abs [8] without the concentration step was in the same range as the detection
limit reported for a similar sandwich ELISA using polyclonal antibodies later produced by Che-
mogen [17], and further on by the Clearview ELISA, in the range of 1 ng/ml. In the studies uti-
lizing the commercial tests no attempt to concentrate the urine was made, except for one study,
where concentration of the urine by centrifugation through a 10 K molecular filter yielded a
modest increase in sensitivity (from 33 to 38%) [18].
Table 4. Detection of LAM by the Uri-TB-direct test in urine of patients with microbiologically verified TB.
Patient Pulmonary (P)/ Extrapulmonary (E) Sputum smear microscopy* Sputum PCR* Mtb culture* Uri-TB-direct (OD)
1 E (urogenital) ND** ND Pos Neg (0,21)
2 P Pos Pos Pos Pos (1,00)
3 E (abscess) Neg Neg Pos Pos (0,62)
4 P Neg Pos Pos Neg (0,27)
5 P Pos Pos Pos Pos (0,83)
6 P Neg Pos Pos Neg (0,29)
7 P Neg Neg Pos Pos (0,58)
8 E (ocular) Neg ND Pos Pos (0,43)
9 E (lymph node) ND ND Pos Pos (1,36)
10 P Neg Pos Neg Pos (1,00)
11 P Neg Neg Pos Pos (0.77)
12 E (lymph node) ND ND Pos Pos (0.78)
13 E (pleural) Neg Neg Pos Pos (0.36)
14 E (lymph node) ND ND Pos Pos (0.94)
15 P Neg Neg Pos Pos (0.37)
16 E (lymph node) ND ND Pos Pos (0,64)
17 P ND ND Pos Pos (1,14)
Mean OD 0,49
Results in optical density (OD) at absorbance 450 n.
* Sputum samples were liqueﬁed and decontaminated using N-acetyl-L-cysteine and NaOH (ﬁnal concentration 1.5%). Portions of the decontaminated
pellet were used for microscopy, culture and PCR. Smear microscopy was performed using auramine staining. For culture the material was inoculated into
a Mycobacteria Growth Indicator Tube (MGIT) (Becton Dickinson, USA) and solid Lowenstein Jensen medium and incubated for up to 42 days. The
Cobas TaqMan MTB test (Roche Diagnostics, Basel, Switzerland) was used for PCR.
** Not done
doi:10.1371/journal.pone.0123457.t004
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In our small pilot study of HIV-negative patients with verified TB and controls the specifici-
ty of our test was 100% and the sensitivity 82%. Our results are in stark positive contrast to a
range of studies using the commercial tests with polyclonal anti-LAM Abs where the sensitivity
of the tests in HIV-negative TB patients was very low (mean 14%) and are better than what is
found in HIV-positive patients (mean 51%) [12]. In a next step the Uri-TB-direct assay in a
simplified format will be evaluated in cohorts from different settings in high and low endemic
areas and in various patient populations.
In memoriam
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